Olartan-Plus (Olmesartan Medoxomil, Hydrochlorothiazide)

Olmesartan medoxomil and hydrochlorothiazide, the active ingredient in Olartan-Plus, is an Angiotensin II receptor blocker (ARB) combined with a thiazide diuretic presented as an oral tablet for oral use. It is used to lower high blood pressure in adult patients.

GNH USA supplies Olartan-Plus as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable sourcing for regulated markets.

Olartan-Plus, which combines an ARB and a thiazide diuretic, is indicated for the management of hypertension.

- Hypertension (essential): reduces systolic and diastolic blood pressure, aiding achievement of guideline‑recommended targets. - Hypertension requiring combination therapy: provides dual blockade of the renin‑angiotensin system and diuresis when a single agent does not achieve control. - Hypertension with fluid retention: adds a thiazide diuretic effect to lower plasma volume, enhancing overall blood pressure reduction. - Hypertension in patients with metabolic syndrome: improves blood pressure while modestly affecting electrolyte balance.

Olartan-Plus may be associated with a range of adverse reactions, varying in frequency and severity.

Common Side Effects: - Dizziness - Headache - Fatigue - Increased urination

Serious or Rare Side Effects: - Severe hypotension - Acute kidney injury - Hyperkalemia - Allergic reactions (rash, angioedema)

When prescribing Olartan-Plus, clinicians should consider several precautionary measures to ensure safe use. - Renal impairment: monitor kidney function and adjust therapy as needed. - Electrolyte imbalance: check serum potassium and sodium levels regularly. - Concomitant diuretics: assess risk of excessive diuresis and hypotension. - Pregnancy: avoid use unless benefits outweigh potential risks. - Elderly patients: start at lower dose and monitor for orthostatic symptoms. - Store at ambient temperature: keep below 25 °C in the original packaging, protected from moisture.

Olartan-Plus can interact with other medicines, affecting its antihypertensive efficacy or safety profile.

Major Interactions (Avoid): - Potassium-sparing diuretics or supplements: may cause hyperkalemia. - NSAIDs (e.g., ibuprofen): can reduce antihypertensive effect and impair renal function. - Lithium: increased risk of lithium toxicity.

Moderate Interactions (Monitor Closely): - ACE inhibitors or other ARBs: additive blood pressure lowering, risk of hypotension. - Antihypertensive agents (beta‑blockers, calcium channel blockers): may require dose adjustments. - Antidiabetic drugs: monitor blood glucose as diuretics can affect glucose control.